Adenosine Receptor Expression in Two Different Human Cancer Cell Lines at Molecular Level (2010)

Background: The metabolically active tumor cells may be characterized by a pronounced adenosine release that regulates the growth and development of the tumor. Consequently, the expression pattern of defined receptor subtypes will be an important determinant for specific effects of adenosine on the control of tumor cell growth. In recent studies, the expression profile, signal transduction, molecular function and cell growth modulation of adenosine receptors in the human breast cancer cell lines has been reported. To investigate the possible roles of adenosine receptors in other types of human cancers, in this study, we characterized the expression profile of adenosine receptors in two different human cancer cell lines: prostate carcinoma cell line (Du-145) and lung adenocarcinoma cell line (Calu-6). Our purpose is to test the hypothesis that diverse human cancer cell lines, according to their adenosine receptor subclass status, would show differential growth modulation. Methods: RNA was extracted and reverse transcribed to cDNA. PCR primers were synthesized from human adenosine receptor cDNA sequences. PCR was performed under optimized condition for each receptor subtype. The PCR products were separated on agarose gels. Results: All two human cancer cell lines studied contained detectable amounts of mRNA specific for adenosine receptor except A 3 subtypes Conclusion: In conclusion the differentially expressed genes identified in this study might provide new insights into the possible roles of adenosine receptors on cell growth and development. Key Words: Prostate; lung; Human cancer; Cell line; RT-PCR; Adenosine receptor References 1.  Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther. 2003; 100(1):31-48. 2. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther. 2008; 117(1):123-40. 3.  Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53(4):527-52. 4. Panjehpour M, Karami-Tehrani F. Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res. 2007; 16(12):575-85. 5. Panjehpour M, Castro M, Klotz KN. Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal. Br J Pharmacol. 2005; 145(2):211-8. 6. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, et al . Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol. 2002; 119(4):923-33. 7. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002; 22(3):364-73. 8.  Tey HB, Khoo HE, Tan CH. Adenosine modulates cell growth in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun.1992; 187(3):1486-92. 9. Yao Y, Sei Y, Abbracchio MP, Jiang JL, Ki m YC, Jacobson KA. Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem Biophys Res Commun. 1997; 232(2):317-22. 10. Shand RL, Gelmann EP. Molecular biology of prostate-cancer pathogenesis. : Curr Opin Urol. 2006; 16(3):123-31. 11. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther. 2007; 7(10):1423-37. 12. Nandigama R, Padmasekar M, Wartenberg M, Sauer H.  Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor activation, and growth stimulation of prostate cancer cells. J Biol Chem. 2006; 281(9):5686-93. 13. Janssens R, Boeynaems JM. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br J Pharmacol. 2001; 132(2):536-46. 14. Zimmermann H. Extracellular purine metabolism. Drug Dev Res. 1996; 39(3-4):337-52. 15. Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, Fishman P.  The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res. 2004; 10(13):4472-9. 16. Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, et al. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A (3) adenosine subtype. J Cell Physiol. 2007; 211(3):826-36. 17.  Panjehpour M, Karami-Tehrani F. An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines. Int J Biochem Cell Biol. 2004; 36(8):1502-9. 18.  Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, Ochaion A, et al.  Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res. 2003; 23(3A):2077-83. 19.  Ohana G, Bar-Yehuda S, Barer F, Fishman P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol. 2001; 186(1):19-23. 20.  Preston A, Frydenberg M, Haynes JM.  A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells. Br J Pharmacol. 2004; 141(2):302-10. 21.  Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, Jacobson KA.  A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care. 2006; 10(2):R65. 22.  Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, et al. Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol. 2003; 171(1):338-45.